Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Journey Medical Corp DERM

Healthcare
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.


NDAQ:DERM - Post by User

Journey Medical Corp
<< Previous
 Bullboard Posts
User Avatar Image
(200)
•••
Post by whytestockson Oct 25, 2024 12:31pm
30 Views
Post# 36282237

Journey Medical Corporation Announces DFD-29 Data Presented

Journey Medical Corporation Announces DFD-29 Data Presented
News; $DERM Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferencePoster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea&#xAE;) in Healthy Subjects With its modified-release formulation, DFD-29 (40 mg) provides higher dermal conce...DERM - Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities